Fujifilm of Japan is about to boost production of a drug to treat Ebola fever. Wall Street Journal states that product in an equivalent of 20 thousand full course treatments as well as 300 thousand more worth of API will be produced. The aniviral drug Avigan…Read more
A leading Geman generics manufacturer Stada announced on October 13, 2014 that it is in-licensing a biosimilar of Forteo (teriparatide) from Richter-Helm BioTec. It will launch the product in Europe in 2019 after the patent on Eli Lilly’s original Forteo expires in December 2018. Teriparatide is a recombinant form of a human parathyroid…Read more
Thomson Reuters forecasts world pharma market to reach 1 trillion dollars this year.Read more
AbbVie’s Humira is the world’s top-selling drug with this year’s second quarter revenue of $3.29 bln according to IMS Health.Read more
European generics manufacturers are switching to biosimilars. Two thirds of drugs losing patent protection in 2014-2020 are biologics or specialty products.Read more
At this time BIOCAD is studying several molecules. The most successful candidate will become a new product in 2018-2019.
Candidate molecules are monoclonal antibodies to PD-1 antigen that stimulate patient immune system to destroy cancer cell. BIOCAD is planning to launch 1-2 new generation drugs every year starting in…Read more
The market is biologics may exceed 250 bln USD by 2020. Biosimilars, copies of biologics, are becoming more popular. According to Reuters 245 companies worldwide are currently developing 700 biosimilars.
Biggest players are Teva, Sandoz, Pfizer, and Amgen. Biosimilars popularity can be explained by their profitability:…Read more
Twelve biologics with total global sales of $67 bln will meet generics competition by 2020.Read more